Biotech pharmaceutical firm Ananda Scientific has announced that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a clinical study evaluating Nantheia ATL5. The candidate uses cannabidiol (CBD) with the company’s proprietary delivery technology as an adjunctive treatment for opioid use disorder.
According to Ananda Scientific representatives, the study is planned to take place at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at the University of California-Los Angeles (UCLA).
Sohail Zaidi, CEO of Ananda Scientific, said the IND approval is the latest in a line of promising developments for the company’s offerings.
“This is the fourth IND approval for our investigational drug Nantheia product line, and it further re-enforces our vision of developing CBD as a therapeutic for a number of key indications,” Zaidi said. “This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need; we are excited to be working with the UCLA team and look forward to this trial advancing.”
This particular trial is being led by principal investigators (PIs)
; and Richard De La Garza, Professor of Psychiatry and Biobehavioral Sciences at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA. Additionally, funding for the trial reportedly is coming from the National Institute on Drug Abuse (NIDA).
PI London said, “The approval of the IND for this important clinical trial is a key milestone for our ongoing research into therapeutic alternatives for opioid use disorder and reversal of the effects of the opioid epidemic.”
With the IND approved we are now moving quickly to get the trial underway,” added De La Garza.